IXICO plc Issue of share options and PDMR dealing
February 07 2025 - 9:00AM
RNS Regulatory News
RNS Number : 3983W
IXICO plc
07 February 2025
IXICO PLC
("IXICO" or
the "Company")
Issue of share
options
7 February 2025 - London, UK. IXICO plc (AIM: IXI, "IXICO" or "the Company") a
global leader in neuroscience imaging,
using its AI-driven platform to help
advance therapy research in neurological disorders, confirms that
share option awards covering 7,413,488 shares, which were proposed
by, and discussed with, the Company's major shareholders in October
2024 (see:
Circular) and approved pursuant
to a resolution supported by 99.76% of the shareholder vote at the
Annual General Meeting of 24 January 2025 have been issued
today.
Full details of the terms of the
options were set out in the Notice of AGM (see:
AGM resolutions)
Ends
Further information:
|
IXICO plc
|
+44 (0) 20 3763 7499
|
|
Bram Goorden, Chief Executive
Officer
Grant Nash, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and
Sole Broker)
|
+44 (0) 20 7220 0500
|
|
Giles Balleny / Dan Hodkinson
(Corporate Finance)
Nigel Birks (Life Science Specialist
Sales)
Harriet Ward (Corporate
Broking)
Michael F Johnson / Tamar Cranford
Smith (Sales)
|
|
|
|
|
|
| |
About IXICO www.IXICO.com
IXICO is dedicated to delivering
insights in neuroscience to help transform the advancement of
investigational therapies for neurological diseases, such as
Huntington's disease, Parkinson's disease and Alzheimer's
disease. The Company's purpose is to
advance medicine and human health by turning data into clinically
meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all
phases of CNS clinical research. IXICO's goal is to be a leading
advocate of artificial intelligence in medical image
analysis.
IXICO has developed and deployed
breakthrough data analytics, at scale, through its remote access
technology platform, to improve the return on investment in drug
development and reduce risk and uncertainty in clinical trials for
the Company's pharmaceutical clients.
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Bram Goorden
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
IXICO plc
|
|
b)
|
LEI
|
2138005M1F59O6HWSA97
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Options over ordinary shares in
IXICO plc
|
|
|
|
|
Identification code
|
ISIN: GB00BFXR4C20
|
|
|
|
|
b)
|
Nature of the transaction
|
Grant of Share Options
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
1 pence
|
4,448,093
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
N/A - single transaction
|
|
- Aggregated volume
|
|
|
|
|
|
- Price
|
|
|
|
|
|
e)
|
Date of the transaction
|
7 February 2025
|
|
f)
|
Place of the transaction
|
Off Market Transaction
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Grant Nash
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Financial Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
IXICO plc
|
|
b)
|
LEI
|
2138005M1F59O6HWSA97
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Options over ordinary shares in
IXICO plc
|
|
|
|
|
Identification code
|
ISIN: GB00BFXR4C20
|
|
|
|
|
b)
|
Nature of the transaction
|
Grant of Share Options
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
1 pence
|
2,965,395
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
N/A - single transaction
|
|
- Aggregated volume
|
|
|
|
|
|
- Price
|
|
|
|
|
|
e)
|
Date of the transaction
|
7 February 2025
|
|
f)
|
Place of the transaction
|
Off Market Transaction
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHUPUAAPUPAGCM
Ixico (LSE:IXI)
Historical Stock Chart
From Jan 2025 to Feb 2025
Ixico (LSE:IXI)
Historical Stock Chart
From Feb 2024 to Feb 2025
